SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp® system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. In addition, Telesis Bio expects to grant the underwriters a 30-day option to purchase up to an additional one million shares of its common stock in the offering. Telesis Bio has applied to have its common stock approved for listing on The Nasdaq Global Market under the ticker symbol “DNAY.”
Jefferies LLC, Cowen and Company, LLC and KeyBanc Capital Markets Inc. are acting as joint book-running managers for the proposed offering.
The offering will be made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by e-mail at Prospectus_Department@Jefferies.com; or by telephone at (877) 821-7388; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, or by e-mail at PostSaleManualRequests@broadridge.com; or by telephone at (833) 297-2926; KeyBanc Capital Markets Inc., Attention: Equity Syndicate, 127 Public Square, 4th Floor, Cleveland, Ohio 44114, or by telephone at (800) 859-1783. Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.
A registration statement relating to the securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Telesis Bio
Telesis Bio is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Telesis Bio’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Telesis Bio’s solution is the BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. Telesis Bio believes the BioXp system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.